Elekta Investor Presentation — May 2020

Document content

Performing in a difficult time

Q4 and year -end report 2019/20

Dr Richard Hausmann, President and CEO

Gustaf Salford, CFO; May 29, 2020Agenda

Driving innovation through leadership

Q4 and full -year performance

Important information

This presentation includes forward -looking statements including, but not limited to, statements relating to

operational and financial performance, market conditions, and other similar matters. These forward -looking

statements are based on current expectations about future events. Although the expectations described in these

statements are assumed to be reasonable, there is no guarantee that such forward -looking statements will

materialize or are accurate. Since these statements involve assumptions and estimates that are subject to risks

and uncertainties, results could differ materially from those set out in the statement. Certain of these risks and

uncertainties are described further in the Annual Report in section “Risks and uncertainties”. Elekta undertakes no

obligation to publicly update or revise any forward -looking statements, whether as a result of new information,

future events or otherwise, except as required by law or stock exchange regulations.

This presentation is intended for investors and analysts only. Some products are still in research and/or not

cleared/approved in all markets. Cancer statistics are given to show the potential market in the respective area and

does not mean that Elekta currently has products to treat these indications.

4Driving innovation through leadership

Everyone with cancer should

have access to and benefit

from precise, personalized

radiotherapyMedicine.Radiation.Precision.

US GenesisCare partnership